Efficacy, Safety and Tolerability Study of TAK-583 in Subjects With Postherpetic Neuralgia

NCT00377598 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

399

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuralgia, Postherpetic

Interventions

DRUG: TAK-583
DRUG: TAK-583
DRUG: TAK-583
DRUG: TAK-583
DRUG: Placebo

Sponsor

Takeda